Learn how Navitas Life Sciences utilized its exceptional expertise to Ensure Successful FIH Study on Solid Malignancies.
The client, a leading Indian multinational pharmaceutical company, sought to advance its oncology portfolio through a Phase-I multicenter, open-label, dose-escalation study in adult patients with advanced solid malignancies. This study presented unique challenges, particularly due to the rarity of FIH oncology studies in India.
Our strategic partnership led to the successful execution of the complex Phase-I clinical trial by
- Developing an effective protocol that secured swift approval.
- Safeguarding patient centricity with a highly experienced team
- Securing quick Ethical Committee Approval
- Ensuring efficient collaboration between the Personal Investigator and sub-investigator
Please complete the form to download the case study and find out how we ensured 100% Successful Complex First-In-Human (FIH) clinical trial.